CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)
Titel:
CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)
Auteur:
Michot, J.-M. Bouabdallah, R. Doorduijn, J.K. Vitolo, U. Kersten, M.J. Chiappella, A. Zinzani, P.L. Pourdehnad, M. Nikolova, Z. Ribrag, V.